Aurinia Pharmaceuticals Inc. (AUPH) Earnings History
Annual and quarterly earnings data from 1998 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 88.5% | 37.1% | 101.5% |
| 2024 | 88.0% | -2.0% | 2.4% |
| 2023 | 91.9% | -52.2% | -44.5% |
| 2022 | 95.8% | -83.2% | -80.7% |
| 2021 | 97.6% | -396.3% | -396.8% |
Download Data
Export AUPH earnings history in CSV or JSON format
Free sign-in required to download data
Aurinia Pharmaceuticals Inc. (AUPH) Earnings Overview
As of March 1, 2026, Aurinia Pharmaceuticals Inc. (AUPH) reported trailing twelve-month net income of $287M, reflecting +51.7% year-over-year growth. The company earned $2.07 per diluted share over the past four quarters, with a net profit margin of 1.0%.
Looking at the long-term picture, AUPH's historical earnings data spans multiple years. The company achieved its highest annual net income of $287M in fiscal 2025, representing a new all-time high.
Aurinia Pharmaceuticals Inc. maintains positive profitability with a gross margin of 0.9%, operating margin of 0.4%, and net margin of 1.0%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including ARGX ($923M net income, 0.4% margin), CANF (-$9M net income, -11.7% margin), AKTX (-$16M net income), AUPH has outperformed on profitability metrics. Compare AUPH vs ARGX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $287M | +4893.1% | $105M | $2.07 | 101.5% | 37.1% |
| 2024 | $6M | +107.4% | -$5M | $0.04 | 2.4% | -2.0% |
| 2023 | -$78M | +27.9% | -$92M | $-0.54 | -44.5% | -52.2% |
| 2022 | -$108M | +40.2% | -$111M | $-0.76 | -80.7% | -83.2% |
| 2021 | -$181M | -76.2% | -$181M | $-1.40 | -396.8% | -396.3% |
| 2020 | -$103M | -16.2% | -$104M | $-0.87 | -204.9% | -208.1% |
| 2019 | -$88M | -37.8% | -$91M | $-1.33 | -27794.0% | -28598.4% |
| 2018 | -$64M | +9.4% | -$56M | $-0.76 | -13848.8% | -12129.2% |
| 2017 | -$71M | -203.9% | -$47M | $-0.92 | -16855.2% | -11205.5% |
| 2016 | -$23M | -25.2% | -$23M | $-0.66 | -13465.3% | -13187.3% |
See AUPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AUPH Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare AUPH vs AGIO
See how AUPH stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is AUPH growing earnings?
AUPH EPS is $2.07, with earnings growth accelerating to +51.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $287M.
What are AUPH's profit margins?
Aurinia Pharmaceuticals Inc. net margin is +1.0%, with operating margin at +0.4%. Below-average margins reflect competitive or cost pressures.
How consistent are AUPH's earnings?
AUPH earnings data spans 1998-2025. The accelerating earnings trend is +51.7% YoY. Historical data enables comparison across business cycles.